View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	3 Months Ended
Document and Entity Information - USD ($)	Mar. 29, 2014	Apr. 18, 2014	Dec. 28, 2013
Document Information [Line Items]
Common Stock, Shares, Outstanding	48,360,000	48,367,013	47,553,841
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL INC
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-27
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 29, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		48,367,013
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float		$ 2,761,272,772.17

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Product revenue	$ 127,023	$ 126,287
Service revenue	172,345	164,951
Revenue	299,368	291,238
Costs and expenses
Cost of products sold	66,586	66,033
Cost of services provided	123,969	120,994
Selling, general and administrative	64,767	57,199
Amortization of other intangibles	4,340	4,249
Operating income	39,706	42,763
Other income (expense)
Interest income	205	97
Interest expense	(2,801)	(8,280)
Other income (expense), net	5,876	1,068
Income from continuing operations, before income taxes	42,986	35,648
Provision (benefit) for income taxes	10,358	9,722
Income from continuing operations, net of income taxes	32,628	25,926
Income (loss) from discontinued operations, net of taxes	(270)	(155)
Net income	32,358	25,771
Less: Net income attributable to noncontrolling interests	(126)	(193)
Net income attributable to common shareowners	$ 32,232	$ 25,578
Basic:
Continuing operations attributable to common shareowners (in dollars per share)	$ 0.69	$ 0.54
Discontinued operations (in dollars per share)	(0.01)	0.00
Net income attributable to common shareowners (in dollars per share)	0.68	0.54
Diluted:
Continuing operations attributable to common shareowners (in dollars per share)	0.67	0.53
Discontinued operations (in dollars per share)	(0.01)	0.00
Net income attributable to common shareowners (in dollars per share)	$ 0.67	$ 0.53

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Net income	$ 32,358	$ 25,771
Foreign currency translation adjustment	(4,543)	(19,933)
Defined benefit plan gains (losses) and prior service costs not yet recognized as components of net periodic pension cost:
Amortization of prior service costs and net gains and losses	(289)	(737)
Comprehensive income, before tax	28,104	6,575
Income tax expense (benefit) related to items of other comprehensive income	19	904
Comprehensive income, net of tax	28,085	5,671
Less: comprehensive income related to noncontrolling interests	(126)	(229)
Comprehensive income attributable to common shareholders	$ 27,959	$ 5,442

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 29, 2014	Dec. 28, 2013
Current assets
Cash and cash equivalents	$ 169,850	$ 155,927
Trade receivables, net	239,998	220,630
Inventories	91,674	89,396
Other current assets	88,459	85,847
Current assets of discontinued businesses	677	750
Total current assets	590,658	552,550
Property, plant and equipment, net	665,609	676,182
Goodwill	230,321	230,701
Other intangibles, net	79,451	84,537
Deferred tax asset	18,711	23,671
Other assets	64,043	61,964
Long-term assets of discontinued businesses	2,970	3,151
Total assets	1,651,763	1,632,756
Current liabilities
Current portion of long-term debt and capital leases	26,683	21,437
Accounts payable	35,253	31,770
Accrued compensation	52,434	58,461
Deferred revenue	54,422	54,177
Accrued liabilities	58,925	56,712
Other current liabilities	9,855	22,546
Current liabilities of discontinued businesses	1,747	1,931
Total current liabilities	239,319	247,034
Long-term debt and capital leases	614,129	642,352
Other long-term liabilities	70,440	70,632
Long-term liabilities	7,615	8,080
Total liabilities	931,503	968,098
Commitments and contingencies
Redeemable noncontrolling interest	21,579	20,581
Shareholders' equity
Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000,000 shares authorized; 80,763,440 issued and 49,106,698 shares outstanding at March 30, 2013 and 79,607,981 issued and 48,220,037 shares outstanding at December 29, 2012	836	825
Capital in excess of par value	2,249,137	2,206,155
Accumulated deficit	(233,241)	(265,473)
Treasury stock, at cost, 31,656,742 shares and 31,387,944 shares at March 30, 2013 and December 29, 2012, respectively	(1,322,354)	(1,305,880)
Accumulated other comprehensive income	1,084	5,357
Total shareholders' equity	695,462	640,984
Noncontrolling interests	3,219	3,093
Stockholder's Equity, Including Noncontrolling Interest and Redeemable Noncontrolling Interest	720,260	664,658
Total liabilities and equity	$ 1,651,763	$ 1,632,756

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 29, 2014	Dec. 28, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	83,624,714	82,522,905
Common Stock, Shares, Outstanding	48,360,000	47,553,841
Treasury stock, shares	35,265,000	34,969,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Cash flows relating to operating activities
Net income	$ 32,358	$ 25,771
Less: Income (loss) from discontinued operations	(270)	(155)
Income from continuing operations	32,628	25,926
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	20,050	20,010
Amortization of debt issuance costs and discounts	435	4,557
Stock-based compensation	6,659	5,904
Deferred income taxes	13,064	6,734
Income (loss) from investments in limited partnerships	(6,104)	90
Other, net	1,380	682
Changes in assets and liabilities:
Trade receivables	(20,224)	(14,234)
Inventories	(2,294)	2,922
Other assets	(5,991)	(4,775)
Accounts payable	6,310	(5,038)
Accrued compensation	(5,839)	(2,651)
Deferred revenue	615	(3,888)
Accrued liabilities	6,933	1,827
Taxes payable and prepaid taxes	(16,497)	(6,938)
Other liabilities	(2,662)	(1,151)
Net cash provided by operating activities	28,463	29,977
Cash flows relating to investing activities
Acquisition of businesses, net of cash acquired	0	(24,141)
Capital expenditures	(11,190)	(6,429)
Purchases of investments	(6,705)	(3,847)
Proceeds from sale of investments and distributions from investments in limited partnerships	11,066	5,589
Other, net	318	46
Net cash used in investing activities	(6,511)	(28,782)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit agreement	49,352	32,803
Proceeds from exercises of stock options	34,841	25,148
Payments on long-term debt, capital lease obligation and revolving credit agreement	(72,589)	(54,902)
Purchase of treasury stock	(20,812)	(11,229)
Other, net	3,064	1,670
Net cash used in financing activities	(6,144)	(6,510)
Discontinued operations
Net cash used in operating activities	(664)	(3)
Net cash provided by discontinued operations	(664)	(3)
Effect of exchange rate changes on cash and cash equivalents	(1,221)	(3,945)
Net change in cash and cash equivalents	13,923	(9,263)
Cash and cash equivalents, beginning of period	155,927	109,685
Cash and cash equivalents, end of period	169,850	100,422
Supplemental cash flow information
Capitalized interest	$ 53	$ 64

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Accumulated (Deficit) Earnings	Accumulated Other Comprehensive Income	Common Stock	Capital in Excess of Par	Treasury Stock	Non-controlling Interest
Components of comprehensive income, net of tax:
Stockholder's Equity, Including Noncontrolling Interest and Redeemable Noncontrolling Interest	$ 664,658	$ (265,473)	$ 5,357	$ 825	$ 2,206,155	$ (1,305,880)	$ 23,674
Net income	32,358	32,232					126
Other comprehensive loss	(4,273)		(4,273)
Comprehensive income, net of tax	28,085						126
Noncontrolling Interest, Increase from Business Combination	(475)						(475)
Noncontrolling Interest, Change in Redemption Value	0				(1,473)		1,473
Tax detriment associated with stock issued under employee compensation plans	2,943
Issuance of stock under employee compensation plans	34,864			11	34,853
Acquisition of treasury shares	(16,474)				0	(16,474)
Stock-based compensation	6,659				6,659
Stockholder's Equity, Including Noncontrolling Interest and Redeemable Noncontrolling Interest	$ 720,260	$ (233,241)	$ 1,084	$ 836	$ 2,249,137	$ (1,322,354)	$ 24,798

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 29, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The condensed consolidated interim financial statements of Charles River Laboratories International, Inc. are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to state fairly our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 28, 2013. Certain reclassifications have been made to prior year financial statements to conform with the current year presentation. These reclassifications have no impact on prior period reported net income or cash flows.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Restructuring and Asset Impairments

3 Months Ended

Mar. 29, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Contract Termination Costs

RESTRUCTURING AND ASSET IMPAIRMENTS

Facilities

North American Research Models

In the first quarter of 2014, we committed to a plan to close our research model production facility located in Michigan by the end of the 2014 and to reassign the sourcing of research models to other facilities in the U.S. As a result of these actions, we reviewed the long-lived assets of this asset group, consisting of land improvements, building and equipment, for potential impairment based on the undiscounted cash flows of the group and considered the potential redeployment and future utilization of the facility's machinery and equipment. Based on the results of this analysis, we recorded an asset impairment and other charges of $690. In addition, we recorded accelerated depreciation of $290 in the first quarter of 2014 reflecting the adjusted remaining useful life and estimated residual value of building and improvements. We anticipate that additional accelerated depreciation for 2014 will amount to approximately $840.

RMS Europe

In 2012, we commenced a consolidation of certain research model operations in Europe. As a result, we adjusted the carrying value of certain facilities impacted by the consolidation plan to fair value through an asset impairment charge in 2012. During the first quarter of 2014, we entered into a purchase and sale agreement to sell a facility impacted by the consolidation plan. The sale closed subsequent to our fiscal quarter end and will be reflected as a gain of approximately $800 in our second quarter financial statements.

Staffing Reductions

We have periodically implemented staffing reductions to improve operating efficiency and profitability at various sites. As a result of these actions, for the three months ended March 29, 2014 and March 30, 2013, we recorded severance and retention charges as shown below. As of March 29, 2014, $2,217 was included in accrued compensation and $1,330 in other long-term liabilities on our consolidated balance sheet.

The following table rolls forward our severance and retention cost liability:



	Three Months Ended
	March 29, 2014			March 30, 2013
Balance, beginning of period	$	2,782		$	3,636
Expense	1,900			297
Payments/utilization	(1,135		)	(498		)
Balance, end of period	$	3,547		$	3,435

The following table presents severance and retention costs by classification on the income statement:



	Three Months Ended
	March 29, 2014		March 30, 2013
Severance charges included in cost of sales	$	1,682	$	227
Severance charges included in selling, general and administrative expense	218		70
Total expense	$	1,900	$	297

The following table presents severance and retention cost by segment:



	Three Months Ended
	March 29, 2014		March 30, 2013
Research models and services	$	1,716	$	86
Preclinical services	63		211
Corporate	121		—
Total expense	$	1,900	$	297

Supplemental Balance Sheet Information

3 Months Ended

Mar. 29, 2014

Supplemental Balance Sheet Information [Abstract]

Supplemental Balance Sheet Information

SUPPLEMENTAL BALANCE SHEET INFORMATION

The composition of net trade receivables is as follows:



	March 29, 2014			December 28, 2013
Client receivables	$	203,107		$	190,423
Unbilled revenue	41,442			35,184
Total	244,549			225,607
Less allowance for doubtful accounts	(4,551		)	(4,977		)
Net trade receivables	$	239,998		$	220,630

The composition of inventories is as follows:



	March 29, 2014		December 28, 2013
Raw materials and supplies	$	15,012	$	15,028
Work in process	11,977		11,715
Finished products	64,685		62,653
Inventories	$	91,674	$	89,396

The composition of other current assets is as follows:



	March 29, 2014		December 28, 2013
Prepaid assets	$	24,316	$	20,058
Deferred tax asset	22,333		29,139
Marketable securities	11,446		11,158
Prepaid income tax	30,348		25,247
Restricted cash	16		245
Other current assets	$	88,459	$	85,847

The composition of net property, plant and equipment is as follows:



	March 29, 2014			December 28, 2013
Land	$	40,070		$	40,157
Buildings	695,278			694,074
Machinery and equipment	374,180			367,244
Leasehold improvements	38,404			37,959
Furniture and fixtures	24,448			24,013
Vehicles	3,882			3,859
Computer hardware and software	112,661			112,328
Construction in progress	36,191			42,075
Total	1,325,114			1,321,709
Less accumulated depreciation	(659,505		)	(645,527		)
Net property, plant and equipment	$	665,609		$	676,182

Depreciation is calculated for financial reporting purposes using the straight-line method based on the estimated useful lives of the assets. Depreciation expense for the three months ended March 29, 2014 and March 30, 2013 was $15,710 and $15,761, respectively.

The composition of other assets is as follows:



	March 29, 2014		December 28, 2013
Deferred financing costs	$	6,692	$	7,126
Cash surrender value of life insurance policies	26,780		26,507
Investments in limited partnerships	18,973		17,911
Other assets	11,598		10,420
Other assets	$	64,043	$	61,964

The composition of other current liabilities is as follows:



	March 29, 2014		December 28, 2013
Accrued income taxes	$	6,662	$	18,773
Current deferred tax liability	1,620		1,960
Accrued interest and other	1,573		1,813
Other current liabilities	$	9,855	$	22,546

The composition of other long-term liabilities is as follows:



	March 29, 2014		December 28, 2013
Deferred tax liability	$	14,840	$	14,988
Long-term pension liability	15,864		16,219
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan	29,971		28,708
Other long-term liabilities	9,765		10,717
Other long-term liabilities	$	70,440	$	70,632

Marketable Securities and Investments in Limited Partnerships	3 Months Ended
	Mar. 29, 2014
Marketable Securities and Equity-Method Affiliates [Abstract]
Marketable Securities and Equity-Method Affiliates	MARKETABLE SECURITIES AND INVESTMENTS IN LIMITED PARTNERSHIPS Marketable Securities Our investments in marketable securities are reported at fair value and consist of time deposits with original maturities ranging from three months to one year. The carrying value for these time deposits approximates fair value and, accordingly, there are no unrealized gains or losses reflected on the consolidated balance sheet. As of March 29, 2014, and December 28, 2013, we held $11,446 and $11,158 of marketable securities, respectively. Investments in Venture Capital Limited Partnerships We have invested in several venture capital limited partnerships that invest in start-up companies in the life sciences industry. Our total commitment to these entities as of March 29, 2014 is $35,000 of which we have funded $13,829 to date. During the quarter ended March 29, 2014, we received dividends in cash and in securities totaling $6,498. Our ownership interest in these limited partnerships ranges from 3.8% to 12.1%. These limited partnerships prepare quarterly financial statements following investment company accounting guidelines, whereby investments are adjusted to fair value with resulting gains and losses recorded in earnings. These entities estimate the fair value of non-publicly traded investments based on all available information, including value implied by the pricing of subsequent preferred share offerings and the net present value of future cash flows. We account for these investments under the equity-method, whereby we record our portion of the investment gains and losses as reported in the fund's financial statements on a quarterly lag each reporting period. In addition, we adjust the carrying value of these investments to reflect our estimate of changes to fair value since the fund's financial statements based information from the fund's management team, market prices of known public holdings of the fund and other information. Our investments in these limited partnerships are subject to a high degree of volatility and are generally higher risk relative to other investments we may make. We report gains and losses from our limited partnership investments in other income (expense), net. We recognized gains (losses) of $6,104 and $(90) for the three months ended March 29, 2014 and March 30, 2013, respectively, related to these investments. As of March 29, 2014, these investments had a carrying value of $18,973, which is reported in other assets on the consolidated balance sheets.

Fair Value

3 Months Ended

Mar. 29, 2014

Fair Value Disclosures [Abstract]

Fair Value

FAIR VALUE

Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:


•	Time deposits—Valued at their carrying amount, which approximates fair value, as reported by the financial institutions that hold our securities.


•	Investments in life insurance policies—Valued at cash surrender value based on fair value of underlying investments.


•	Redeemable noncontrolling interest—Valued primarily using the income approach based on estimated future cash flows of the underlying business based on our projected financial data discounted by a weighted average cost of capital. Significant assumptions include a discount rate of 18% and a long-term pretax operating margin of 32%.

Assets and liabilities measured at fair value on a recurring basis are summarized below:



	Fair Value Measurements at March 29, 2014
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	11,446	$	—	$	11,446
Life policies	—		19,747		—		19,747
Total assets measured at fair value	$	—	$	31,193	$	—	$	31,193
Redeemable noncontrolling interest	—		—		21,579		21,579
Total liabilities measured at fair value	$	—	$	—	$	21,579	$	21,579



	Fair Value Measurements at December 28, 2013
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	11,158	$	—	$	11,158
Life policies	—		19,534		—		19,534
Total assets measured at fair value	$	—	$	30,692	$	—	$	30,692
Redeemable noncontrolling interest	—		—		20,581		20,581
Total liabilities measured at fair value	$	—	$	—	$	20,581	$	20,581

The book value of our term and revolving loans, which are variable rate loans carried at amortized cost, approximates fair value based current market pricing of similar debt.

Concurrent with the acquisition of Vital River in 2013, we entered into a joint venture agreement with the noncontrolling interest holders that provide us with the right to purchase the remaining 25% of the entity for cash at its then appraised value beginning in January 2016. Additionally, the noncontrolling interest holders were granted the right to require us to purchase the remaining 25% of the entity at its then appraised value beginning in January 2016 for cash. These rights are accelerated in certain events. As the noncontrolling interest holders can require the Company to purchase for cash the remaining 25% interest, we classify the carrying amount of the noncontrolling interest above the equity section and below liabilities on the consolidated balance sheet and we adjust the carrying amount to fair value each quarter end. Adjustments to fair value, which is deemed to be Level 3 as the fair value is based on unobservable inputs, are recorded through additional paid-in capital.



	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Three Months Ended
Redeemable Noncontrolling Interest (Liability)	March 29, 2014			March 30, 2013
Beginning balance	$	20,581		$	—
Transfers in and/or out of Level 3	—			—
Total gains or losses (realized/unrealized):
Purchases, issuances and settlements				8,963
Included in other income (expense)	1			38
Change in balance due to foreign currency translation	(476		)	37
Included in additional paid-in capital	1,473			—
Ending balance	$	21,579		$	9,038

We enter into derivative instruments to hedge foreign currency exchange risk to reduce the impact of changes to foreign currency rates on our financial statements. During the three months ended March 29, 2014, we recognized $575 of net hedge losses associated with forward currency contracts open during the period. As of March 29, 2014, there were no open forward currency contracts.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 29, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS

The following table displays the gross carrying amount and accumulated amortization of definite-lived intangible assets by major class:



	March 29, 2014					December 28, 2013
	Gross Carrying Amount		Accumulated Amortization & Impairment Loss			Gross Carrying Amount		Accumulated Amortization & Impairment Loss
Backlog	$	2,916	$	(2,533	)	$	2,916	$	(2,507	)
Client relationships	307,383		(238,138		)	311,507		(238,002		)
Trademarks and trade names	5,398		(5,012		)	5,399		(4,997		)
Standard operating procedures	2,754		(1,645		)	2,754		(1,498		)
Other identifiable intangible assets	10,481		(5,591		)	10,432		(4,905		)
Total other intangible assets	$	328,932	$	(252,919	)	$	333,008	$	(251,909	)

Additionally, as of both March 29, 2014 and December 28, 2013, other intangible assets, net, included $3,438 of indefinite-lived intangible assets.

The changes in the gross carrying amount and accumulated impairment loss of goodwill are as follows:



				Adjustments to Goodwill
	December 28, 2013			Acquisitions		Foreign Exchange			March 29, 2014
Research Models and Services
Gross carrying amount	$	83,551		$	—	$	(361	)	$	83,190
Preclinical Services
Gross carrying amount	1,152,150			—		(19		)	1,152,131
Accumulated impairment loss	(1,005,000		)						(1,005,000		)
Total
Gross carrying amount	$	1,235,701		$	—	$	(380	)	$	1,235,321
Accumulated impairment loss	(1,005,000		)						(1,005,000		)
Goodwill, net	$	230,701							$	230,321

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Debt and Capital Lease Obligations

3 Months Ended

Mar. 29, 2014

Debt Disclosure [Abstract]

Long-Term Debt and Capital Lease Obligations

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

Long-Term Debt

Long-term debt consists of the following:



	March 29, 2014			December 28, 2013
Term loans	$	404,250		$	409,500
Revolving credit facility	235,603			253,308
Other long-term debt	241			241
Total debt	640,094			663,049
Less: current portion of long-term debt	(26,491		)	(21,241		)
Long-term debt	$	613,603		$	641,808

On May 29, 2013, we amended and restated our credit agreement dated September 23, 2011 to repay loans outstanding under the previous agreement, to retire our 2.25% Senior Convertible Debentures (2013 Notes), and to extend the maturity date of our credit agreement under a new $970,000 agreement (the $970M Credit Facility). The $970M Credit Facility provides for a $420,000 U.S. term loan facility and a $550,000 multi-currency revolving credit facility. The revolving credit facility may be drawn in U.S. Dollars, Euros, Pound Sterling, or Japanese Yen, subject to sub-limits by currency. Under specified circumstances, we have the ability to expand the term loan and/or revolving credit facility by up to $350,000 in the aggregate. Certain financing costs associated with the $970M Credit Facility were capitalized as deferred financing costs and will be amortized over the life of the agreement using the effective interest method.

The $420,000 U.S. term loan matures in quarterly installments through maturity on May 29, 2018. The revolving credit facility also matures on May 29, 2018 and requires no scheduled payment before this date. The interest rates applicable to the $970M Credit Facility are variable and are based on an applicable rate plus a spread determined by our leverage ratio. As of March 29, 2014, the interest rate spread for the adjusted LIBOR was 1.25%.

The $970M Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to our business and negative and affirmative covenants. As of March 29, 2014, we were compliant with all financial covenants specified in the credit agreement.

We had $5,109 outstanding under letters of credit as of March 29, 2014.

Principal maturities of existing debt for the periods set forth in the table below, are as follows:



Twelve Months Ending
March 2015	$	26,491
March 2016	42,000
March 2017	52,500
March 2018	73,500
March 2019	445,603
Total	$	640,094

We have capital leases for equipment. These leases are capitalized using interest rates considered appropriate at the inception of the lease. Capital lease obligations amounted to $717 and $740 at March 29, 2014 and December 28, 2013, respectively.

Equity

3 Months Ended

Mar. 29, 2014

Stockholders' Equity Note [Abstract]

Equity

EQUITY

Earnings Per Share

Basic earnings per share for the three months ended March 29, 2014 and March 30, 2013 was computed by dividing earnings available to common shareholders for these periods by the weighted average number of common shares outstanding in the respective periods adjusted for contingently issuable shares, such as unvested restricted stock. The weighted average number of common shares outstanding for the three months ended March 29, 2014 and March 30, 2013 has been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share for these periods.

Options to purchase 609,923 shares and 2,684,236 shares were outstanding in each of the three months ended March 29, 2014 and March 30, 2013, respectively, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted average shares outstanding for the three months ended March 29, 2014 and March 30, 2013 excluded the weighted average impact of 1,188,699 and 1,149,622 shares, respectively, of non-vested restricted stock awards.

The following table reconciles of the numerator and denominator in the computations of the basic and diluted earnings per share.



	Three Months Ended
	March 29, 2014			March 30, 2013
Numerator:
Income from continuing operations for purposes of calculating earnings per share	$	32,502		$	25,733
Loss from discontinued businesses	(270		)	$	(155	)
Denominator:
Weighted-average shares outstanding—Basic	47,090,830			47,658,995
Effect of dilutive securities:
Stock options and contingently issuable restricted stock	1,060,554			777,054
Weighted-average shares outstanding—Diluted	48,151,384			48,436,049
Basic earnings per share from continuing operations attributable to common shareholders	$	0.69		$	0.54
Basic earnings (loss) per share from discontinued operations attributable to common shareholders	$	(0.01	)	$	—
Diluted earnings per share from continuing operations attributable to common shareholders	$	0.67		$	0.53
Diluted earnings (loss) per share from discontinued operations attributable to common shareholders	$	(0.01	)	$	—

Treasury Shares

For the three months ended March 29, 2014 and March 30, 2013, we repurchased 183,300 shares of common stock for $9,820 and 157,283 shares of common stock for $6,458, respectively, through open market purchases made in reliance on Rules 10b5-1 and 10b-18 of the Securities Exchange Act of 1934, as amended. Additionally, our 2007 Incentive Plan permits the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. During the three months ended March 29, 2014 and March 30, 2013, we acquired 112,747 shares for $6,654 and 111,515 shares for $4,471, respectively, as a result of such withholdings.

Share repurchases for the three months ended March 29, 2014 and March 30, 2013 were as follows:



	Three Months Ended
	March 29, 2014		March 30, 2013
Number of shares of common stock repurchased	296,047		268,798
Total cost of repurchase	$	16,474	$	10,929

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income Taxes
$ in Thousands

3 Months Ended

Mar. 29, 2014

USD ($)

Income Tax Disclosures [Line Items]

Unrecognized Tax Benefits, Period Increase (Decrease)

$ 2,563

Income Taxes

INCOME TAXES

The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statements of income:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income from continuing operations before income taxes	$	42,986		$	35,648
Effective tax rate	24.1		%	27.3		%
Provision for income taxes	$	10,358		$	9,722

Our overall effective tax rate was 24.1% in the first quarter of 2014 and 27.3% in the first quarter of 2013. The decrease was primarily attributable to a $1,837 release of an uncertain tax position resulting from the ability to offset a capital gain from an investment in a limited partnership. The effective tax rate for the first quarter of 2014 reflects a discrete benefit of $238 resulting from the settlement of a Canadian tax controversy related to headquarter service charges for the tax years 2006 through 2009. In addition, in the first quarter of 2014, we reorganized our UK RMS operations. The purpose of this reorganization was to streamline the legal entity structure in order to improve the operating efficiency, facilitate acquisitions, and provide tax benefits. The reorganization, which did not involve reductions of personnel or facility closures, resulted in a one-time tax cost in the first quarter of 2014 of $1,220 due primarily to the write-off of deferred tax assets.

In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11 “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” The ASU requires an entity to present an unrecognized tax benefit as a reduction of the deferred tax asset for a net operating loss, or similar loss or tax credit carryforward, as opposed to a liability, unless certain circumstances exist. The ASU does not require new disclosures and may be adopted either prospectively or retrospectively. The ASU become effective during our first fiscal quarter and we adopted the provisions of ASU 2013-11 retrospectively. The adoption of the ASU decreased net non-current deferred tax assets and decreased the associated long-term tax liabilities related to unrecognized tax benefits by $9,271 and $11,865 as of March 29, 2014 and December 28, 2013, respectively.

During the first quarter of 2014, our unrecognized tax benefits recorded decreased by $2,563 to $15,912 due primarily to the settlement of a Canadian tax controversy related to headquarter service charges for tax years 2006 through 2009 and the release of a portion of the uncertain tax position associated with an acquisition agreement termination fee to offset a capital gain.

The amount of unrecognized income tax benefits that would impact the effective tax rate favorably decreased by $2,719 to $14,293. The decrease was due primarily to the settlement of a Canadian tax controversy related to headquarter service charges for tax years 2006 through 2009 and the release of a portion of the uncertain tax position associated with an acquisition agreement termination fee to offset a capital gain. The amount of accrued interest on unrecognized tax benefits decreased by

by $24 to $667 in the first quarter of 2014 primarily due to the settlement of the Canadian tax controversy.

We conduct business in a number of tax jurisdictions. As a result, we are subject to tax audits in jurisdictions including, but not limited to, the United States, the United Kingdom, Japan, France, Germany, and Canada. With few exceptions, we are no longer subject to U.S. and international income tax examinations for years before 2010 although carryforward attributes that were generated prior to 2010 may still be adjusted upon examination by taxing authorities if they either have been, or will be, used in a future period. As of March 29, 2014, we anticipate the statue of limitations to expire within the next twelve months for a year which includes an uncertain tax position associated with an acquisition agreement termination fee. However, we do not expect the liability associated with this uncertain tax position to decrease until the statute expires on the year in which a carryforward attribute is utilized.

We and certain of our subsidiaries are currently under audit by various tax authorities in the U.S., Germany, and France. We do not believe that resolution of these controversies will have a material impact on our financial position or results of operations.

On December 30, 2013, the French government enacted anti-hybrid provisions in an attempt to further restrict the ability of companies to deduct interest in France for 2013 and beyond. We believe this new tax law should not apply to further restrict the deduction of interest by our French affiliates. However, future changes in or clarifications to the French anti-hybrid provisions could result in the disallowance of interest deducted by our French affiliates resulting in an increase to our effective tax rate in 2014 and beyond

On February 25, 2013, the German government enacted a tax law change that restricts the deductibility of losses in Germany. As of March 29, 2014, we believe that this new tax law should not apply to restrict the deduction of losses by our German affiliates. However, future changes in or clarifications to the German tax law may result in disallowing losses currently being deducted by our German affiliates and a corresponding increase to our effective tax rate in 2014 and beyond.

In accordance with our policy, the remaining undistributed earnings of our non-U.S. subsidiaries remain indefinitely reinvested as of the end of the first quarter of 2014 as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free.

The income tax expense (benefit) related to items of other comprehensive income are as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income tax benefit related to foreign currency translation adjustment	$	(105	)	$	662
Income tax expense related to change in unrecognized pension gains, losses and prior service costs	124			242
Income tax expense related to items of other comprehensive income	$	19		$	904

UNITED STATES

Income Tax Disclosures [Line Items]

Unrecognized Tax Benefits, Period Increase (Decrease)

$ (1,837)

Employee Benefits

3 Months Ended

Mar. 29, 2014

Compensation and Retirement Disclosure [Abstract]

Employee Benefits

EMPLOYEE BENEFITS

The following table provides the components of net periodic benefit cost for our defined benefit plans for the three month period ended:



	Pension Benefits						Supplemental Retirement Benefits
	March 29, 2014			March 30, 2013			March 29, 2014		March 30, 2013
Service cost	$	842		$	847		$	189	$	161
Interest cost	3,211			2,810			252		177
Expected return on plan assets	(4,278		)	(3,656		)	—		—
Amortization of prior service cost (credit)	(159		)	(150		)	165		165
Amortization of net loss (gain)	223			690			63		63
Net periodic (benefit) cost	$	(161	)	$	541		$	669	$	566

The above table excludes amortization of net deferred gains of $3 and $31 for the three month periods ended March 29, 2014, and March 30, 2013, respectively, related to our post-retirement health and life insurance plans. During 2014, we expect to contribute $6,477 to our pension plans.

Stock Plans and Stock-Based Compensation

3 Months Ended

Mar. 29, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Plans and Stock Based Compensation

STOCK PLANS AND STOCK-BASED COMPENSATION

We have stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock and performance share units. For a complete description of these plans please refer to our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 28, 2013.

The following table provides the financial statement line items in which stock-based compensation is reflected:



	Three Months Ended
	March 29, 2014			March 30, 2013
Stock-based compensation expense included in:
Cost of sales	$	1,353		$	1,369
Selling, general and administration	5,306			4,535
Stock-based compensation, before income taxes	6,659			5,904
Provision for income taxes	(2,364		)	(2,043		)
Stock-based compensation, net of tax	$	4,295		$	3,861

Performance Based Stock Award Program

In the first quarters of 2014 and 2013, we issued performance-based stock awards (performance share units, or PSUs) to certain employees. Each performance share unit is settled in one share of our common stock three years from the grant date if the participant satisfies the service requirement. In addition, the number of common stock issued for each PSU at the end of the three-year vesting period is adjusted based on a performance condition linked to the Company's financial performance, which is generally earnings per share with certain defined adjustments, and is further adjusted based on a market condition, which is calculated based on the Company's stock price performance relative to a peer group over the three year vesting period. The fair value of the market condition is reflected in the fair value of the award at grant date. Each reporting period, we record a ratable amount of stock-based compensation for the estimated number of common shares expected to be issued upon the vestings of the PSUs based on our estimated outcome for the performance condition.

During the first quarter of 2014, we issued 214,823 performance share units using a fair value per share of $67.82. The maximum amount of common shares to be issued upon vesting is 429,646. During the first quarter of 2013, we issued 163,847

performance share units using a fair value per share of $44.47. The maximum amount of common shares to be issued upon vesting of these PSUs is 327,694. For the period ended March 29, 2014, we recognized $1,034 of stock-based compensation related to performance share units granted in 2014 and 2013.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Various lawsuits, claims and proceedings of a nature considered normal to our business are pending against us. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect our consolidated financial statements. In early May 2013, the Company commenced an investigation into inaccurate billing with respect to certain government contracts. The Company promptly reported these matters to the relevant government contracting officers, the Department of Health and Human Services' Office of the Inspector General, and the Department of Justice, and we are cooperating with these agencies to ensure the proper repayment and resolution of this matter. The Company identified approximately $1,500 in excess amounts billed on these contracts since January 1, 2007 and reserved such amount. Because of the preliminary stage of discussions with the government and complex nature of this matter, the Company believes that it is reasonably possible that additional losses may be incurred. However, the Company cannot at this time estimate the potential range of loss beyond the current reserve of $1,500. On July 27, 2012, a Mauritius supplier of large animal models submitted an Application for Arbitration with The Permanent Secretariat, The Permanent Court of Arbitration, The Mauritius Chamber of Commerce and Industry in Port Louis, Mauritius. The supplier asserted that the Company failed to pay certain invoices and the supplier was therefore permitted to terminate the supply agreement. The Company filed a counterclaim asserting that the supplier had failed to meet its contractual obligations under the supply agreement. The arbitration hearing relating to this contract dispute took place in Mauritius from August 13-15, 2013 and final arguments were presented in March 2014. While no prediction may be made as to the outcome of arbitration, the Company intends to defend against this proceeding vigorously and therefore an estimate of the possible loss or range of loss cannot be made.

Business Segment Information

3 Months Ended

Mar. 29, 2014

Segment Reporting [Abstract]

Business Segment Information

BUSINESS SEGMENT INFORMATION

We report two business segments, Research Models and Services (RMS) and Preclinical Services (PCS). Our RMS segment includes sales of Research Models, Genetically Engineered Models and Services (GEMS), Insourcing Solutions (IS), Research Animal Diagnostic Services (RADS), Discovery Services (DS), Endotoxin and Microbial Detection (EMD) products and services, and Avian Vaccine products and services. Our PCS segment includes services required to take a drug through the development process, which includes DS, safety assessment and Biologics Testing Services.

The following table presents sales and other financial information by business segment.



	Three Months Ended
	March 29, 2014		March 30, 2013
Research Models and Services
Revenue	$	185,615	$	182,489
Gross margin	80,979		80,435
Operating income	53,540		55,303
Depreciation and amortization	10,690		9,873
Capital expenditures	6,868		4,010
Preclinical Services
Revenue	$	113,753	$	108,749
Gross margin	27,834		23,776
Operating income	12,033		8,060
Depreciation and amortization	9,361		10,137
Capital expenditures	4,322		2,418

A reconciliation of segment operating income to consolidated operating income is as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Total segment operating income	$	65,573		$	63,363
Unallocated corporate overhead	(25,867		)	(20,600		)
Consolidated operating income	$	39,706		$	42,763

Revenue for each significant product or service area are as follows:



	Three Months Ended
	March 29, 2014		March 30, 2013
Research models	$	99,355	$	103,123
Research model services	53,795		52,154
EMD	32,465		27,212
Total research models and services	185,615		182,489
Total preclinical services	113,753		108,749
Total revenue	$	299,368	$	291,238

A summary of unallocated corporate overhead consists of the following:



	Three Months Ended
	March 29, 2014		March 30, 2013
Stock-based compensation expense	$	3,702	$	3,197
U.S. retirement plans	644		1,300
Audit, tax and related expense	1,906		1,235
Salary and bonus	6,139		4,755
Global IT	2,869		2,586
Employee health, long-term disability and fringe benefit expense	2,319		2,228
Consulting and professional services	1,182		688
Depreciation expense	1,600		1,570
Other general unallocated corporate expenses	5,506		3,041
Total unallocated corporate overhead costs	$	25,867	$	20,600

Other general unallocated corporate expenses consist of various departmental costs including those associated with senior executives, corporate accounting, legal, tax, human resources and treasury.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Discontinued Operations

3 Months Ended

Mar. 29, 2014

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

On March 28, 2011, we disposed of our Phase I clinical business. As part of the disposition we remained the guarantor of a Phase I facility lease. The facility lease runs through January 2021 with remaining lease payments totaling $11,070 as of March 29, 2014. On April 4, 2013, the buyer of our Phase I clinical business filed for Chapter 11 bankruptcy and effective July 1, 2013, we assumed control of the leased property and assumed obligations under the lease consistent with the guarantee. The total carrying amount of the liability for our obligation under the lease as of March 29, 2014 is $9,345 and is reflected on the consolidated balance sheet as a liability of discontinued operations.

The consolidated financial statements classify, as discontinued operations, the assets and liabilities, operating results and cash flows, of businesses that are discontinued for all periods presented. Operating results from discontinued operations are as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income (loss) from operations of discontinued businesses, before income taxes	(25		)	(220		)
Provision (benefit) for income taxes	245			(65		)
Income (loss) from operations of discontinued businesses, net of taxes	$	(270	)	$	(155	)

Assets and liabilities of discontinued operations at March 29, 2014 and December 28, 2013 consisted of the following:



	March 29, 2014		December 28, 2013
Current assets	$	677	$	750
Long-term assets	2,970		3,151
Total assets	$	3,647	$	3,901
Current liabilities	$	1,747	$	1,931
Long-term liabilities	7,615		8,080
Total liabilities	$	9,362	$	10,011

Current and long-term assets include deferred tax assets. Current and long-term liabilities consist primarily of estimated lease payments, less sublease income, for the Phase I facility.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Business Acquisitions (Notes)	3 Months Ended
Business Acquisitions (Notes)	Mar. 29, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS ACQUISITIONS Early Discovery UK On April 1, 2014, we acquired the CRO services division of Galapagos N.V., which includes both the Argenta and BioFocus businesses, and which consist of UK entities and certain Dutch assets including a facility lease and equipment, and the transfer of employees (collectively Early Discovery UK). We expect that the acquisition will enhance our position as a full service, early-stage CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development. The preliminary purchase price of the acquisition is $190,727 in cash and up to an additional $6,887 in contingent consideration. The purchase price includes payment for estimated working capital, which is subject to final adjustment based on the actual working capital of the acquired business. We are currently in the process of determining the allocation of the purchase price to the fair value of assets and liabilities acquired.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Fair Value (Policies)	3 Months Ended
Fair Value (Policies)	Mar. 29, 2014
Fair Value Disclosures [Abstract]
Derivative Instruments	We enter into derivative instruments to hedge foreign currency exchange risk to reduce the impact of changes to foreign currency rates on our financial statements.

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References + Details

Restructuring and Asset Impairments (Tables)

3 Months Ended

Mar. 29, 2014

Restructuring and Related Activities [Abstract]

Schedule of Severance and Retention Costs

The following table rolls forward our severance and retention cost liability:



	Three Months Ended
	March 29, 2014			March 30, 2013
Balance, beginning of period	$	2,782		$	3,636
Expense	1,900			297
Payments/utilization	(1,135		)	(498		)
Balance, end of period	$	3,547		$	3,435

The following table presents severance and retention costs by classification on the income statement:



	Three Months Ended
	March 29, 2014		March 30, 2013
Severance charges included in cost of sales	$	1,682	$	227
Severance charges included in selling, general and administrative expense	218		70
Total expense	$	1,900	$	297

The following table presents severance and retention cost by segment:



	Three Months Ended
	March 29, 2014		March 30, 2013
Research models and services	$	1,716	$	86
Preclinical services	63		211
Corporate	121		—
Total expense	$	1,900	$	297

Supplemental Balance Sheet Information (Tables)

3 Months Ended

Mar. 29, 2014

Supplemental Balance Sheet Information [Abstract]

Composition of Net Trade Receivables

The composition of net trade receivables is as follows:



	March 29, 2014			December 28, 2013
Client receivables	$	203,107		$	190,423
Unbilled revenue	41,442			35,184
Total	244,549			225,607
Less allowance for doubtful accounts	(4,551		)	(4,977		)
Net trade receivables	$	239,998		$	220,630

Composition of Inventories

The composition of inventories is as follows:



	March 29, 2014		December 28, 2013
Raw materials and supplies	$	15,012	$	15,028
Work in process	11,977		11,715
Finished products	64,685		62,653
Inventories	$	91,674	$	89,396

Composition of Other Current Assets

The composition of other current assets is as follows:



	March 29, 2014		December 28, 2013
Prepaid assets	$	24,316	$	20,058
Deferred tax asset	22,333		29,139
Marketable securities	11,446		11,158
Prepaid income tax	30,348		25,247
Restricted cash	16		245
Other current assets	$	88,459	$	85,847

Composition of Net Property, Plant and Equipment

The composition of net property, plant and equipment is as follows:



	March 29, 2014			December 28, 2013
Land	$	40,070		$	40,157
Buildings	695,278			694,074
Machinery and equipment	374,180			367,244
Leasehold improvements	38,404			37,959
Furniture and fixtures	24,448			24,013
Vehicles	3,882			3,859
Computer hardware and software	112,661			112,328
Construction in progress	36,191			42,075
Total	1,325,114			1,321,709
Less accumulated depreciation	(659,505		)	(645,527		)
Net property, plant and equipment	$	665,609		$	676,182

Composition of Other Assets

The composition of other assets is as follows:



	March 29, 2014		December 28, 2013
Deferred financing costs	$	6,692	$	7,126
Cash surrender value of life insurance policies	26,780		26,507
Investments in limited partnerships	18,973		17,911
Other assets	11,598		10,420
Other assets	$	64,043	$	61,964

Composition of Current Liabilities

The composition of other current liabilities is as follows:



	March 29, 2014		December 28, 2013
Accrued income taxes	$	6,662	$	18,773
Current deferred tax liability	1,620		1,960
Accrued interest and other	1,573		1,813
Other current liabilities	$	9,855	$	22,546

Composition of Other Long-Term Liabilities

The composition of other long-term liabilities is as follows:



	March 29, 2014		December 28, 2013
Deferred tax liability	$	14,840	$	14,988
Long-term pension liability	15,864		16,219
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan	29,971		28,708
Other long-term liabilities	9,765		10,717
Other long-term liabilities	$	70,440	$	70,632

Fair Value (Tables)

3 Months Ended

Mar. 29, 2014

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Three Months Ended
Redeemable Noncontrolling Interest (Liability)	March 29, 2014			March 30, 2013
Beginning balance	$	20,581		$	—
Transfers in and/or out of Level 3	—			—
Total gains or losses (realized/unrealized):
Purchases, issuances and settlements				8,963
Included in other income (expense)	1			38
Change in balance due to foreign currency translation	(476		)	37
Included in additional paid-in capital	1,473			—
Ending balance	$	21,579		$	9,038

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and liabilities measured at fair value on a recurring basis are summarized below:



	Fair Value Measurements at March 29, 2014
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	11,446	$	—	$	11,446
Life policies	—		19,747		—		19,747
Total assets measured at fair value	$	—	$	31,193	$	—	$	31,193
Redeemable noncontrolling interest	—		—		21,579		21,579
Total liabilities measured at fair value	$	—	$	—	$	21,579	$	21,579



	Fair Value Measurements at December 28, 2013
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	11,158	$	—	$	11,158
Life policies	—		19,534		—		19,534
Total assets measured at fair value	$	—	$	30,692	$	—	$	30,692
Redeemable noncontrolling interest	—		—		20,581		20,581
Total liabilities measured at fair value	$	—	$	—	$	20,581	$	20,581

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 29, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill and Other Intangible Assets not Subject to Amortization and Other Intangible Assets that Continue to be Subject to Amortization

The following table displays the gross carrying amount and accumulated amortization of definite-lived intangible assets by major class:



	March 29, 2014					December 28, 2013
	Gross Carrying Amount		Accumulated Amortization & Impairment Loss			Gross Carrying Amount		Accumulated Amortization & Impairment Loss
Backlog	$	2,916	$	(2,533	)	$	2,916	$	(2,507	)
Client relationships	307,383		(238,138		)	311,507		(238,002		)
Trademarks and trade names	5,398		(5,012		)	5,399		(4,997		)
Standard operating procedures	2,754		(1,645		)	2,754		(1,498		)
Other identifiable intangible assets	10,481		(5,591		)	10,432		(4,905		)
Total other intangible assets	$	328,932	$	(252,919	)	$	333,008	$	(251,909	)

Schedule of Changes in the Gross Carrying Amount and Accumulated Amortization of Goodwill

The changes in the gross carrying amount and accumulated impairment loss of goodwill are as follows:



				Adjustments to Goodwill
	December 28, 2013			Acquisitions		Foreign Exchange			March 29, 2014
Research Models and Services
Gross carrying amount	$	83,551		$	—	$	(361	)	$	83,190
Preclinical Services
Gross carrying amount	1,152,150			—		(19		)	1,152,131
Accumulated impairment loss	(1,005,000		)						(1,005,000		)
Total
Gross carrying amount	$	1,235,701		$	—	$	(380	)	$	1,235,321
Accumulated impairment loss	(1,005,000		)						(1,005,000		)
Goodwill, net	$	230,701							$	230,321

Long-Term Debt and Capital Lease Obligations (Tables)

3 Months Ended

Mar. 29, 2014

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consists of the following:



	March 29, 2014			December 28, 2013
Term loans	$	404,250		$	409,500
Revolving credit facility	235,603			253,308
Other long-term debt	241			241
Total debt	640,094			663,049
Less: current portion of long-term debt	(26,491		)	(21,241		)
Long-term debt	$	613,603		$	641,808

Schedule of Principal Maturities of Existing Debt Excluding Unamortized Debt Discount

Principal maturities of existing debt for the periods set forth in the table below, are as follows:



Twelve Months Ending
March 2015	$	26,491
March 2016	42,000
March 2017	52,500
March 2018	73,500
March 2019	445,603
Total	$	640,094

Equity (Tables)

3 Months Ended

Mar. 29, 2014

Stockholders' Equity Note [Abstract]

Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share

The following table reconciles of the numerator and denominator in the computations of the basic and diluted earnings per share.



	Three Months Ended
	March 29, 2014			March 30, 2013
Numerator:
Income from continuing operations for purposes of calculating earnings per share	$	32,502		$	25,733
Loss from discontinued businesses	(270		)	$	(155	)
Denominator:
Weighted-average shares outstanding—Basic	47,090,830			47,658,995
Effect of dilutive securities:
Stock options and contingently issuable restricted stock	1,060,554			777,054
Weighted-average shares outstanding—Diluted	48,151,384			48,436,049
Basic earnings per share from continuing operations attributable to common shareholders	$	0.69		$	0.54
Basic earnings (loss) per share from discontinued operations attributable to common shareholders	$	(0.01	)	$	—
Diluted earnings per share from continuing operations attributable to common shareholders	$	0.67		$	0.53
Diluted earnings (loss) per share from discontinued operations attributable to common shareholders	$	(0.01	)	$	—

Schedule of Number of Shares Repurchased and the Total Cost of Repurchase

Share repurchases for the three months ended March 29, 2014 and March 30, 2013 were as follows:



	Three Months Ended
	March 29, 2014		March 30, 2013
Number of shares of common stock repurchased	296,047		268,798
Total cost of repurchase	$	16,474	$	10,929

Income Taxes (Tables)

3 Months Ended

Mar. 29, 2014

Income Tax Disclosure [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The income tax expense (benefit) related to items of other comprehensive income are as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income tax benefit related to foreign currency translation adjustment	$	(105	)	$	662
Income tax expense related to change in unrecognized pension gains, losses and prior service costs	124			242
Income tax expense related to items of other comprehensive income	$	19		$	904

Reconciliation of Provision for Income Taxes on Condensed Consolidated Statements of Operations

The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statements of income:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income from continuing operations before income taxes	$	42,986		$	35,648
Effective tax rate	24.1		%	27.3		%
Provision for income taxes	$	10,358		$	9,722

Employee Benefits (Tables)

3 Months Ended

Mar. 29, 2014

Compensation and Retirement Disclosure [Abstract]

Components of Net Periodic Benefit Cost for Defined Benefit Plans

The following table provides the components of net periodic benefit cost for our defined benefit plans for the three month period ended:



	Pension Benefits						Supplemental Retirement Benefits
	March 29, 2014			March 30, 2013			March 29, 2014		March 30, 2013
Service cost	$	842		$	847		$	189	$	161
Interest cost	3,211			2,810			252		177
Expected return on plan assets	(4,278		)	(3,656		)	—		—
Amortization of prior service cost (credit)	(159		)	(150		)	165		165
Amortization of net loss (gain)	223			690			63		63
Net periodic (benefit) cost	$	(161	)	$	541		$	669	$	566

Stock Plans and Stock-Based Compensation (Tables)

3 Months Ended

Mar. 29, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Expense



	Three Months Ended
	March 29, 2014			March 30, 2013
Stock-based compensation expense included in:
Cost of sales	$	1,353		$	1,369
Selling, general and administration	5,306			4,535
Stock-based compensation, before income taxes	6,659			5,904
Provision for income taxes	(2,364		)	(2,043		)
Stock-based compensation, net of tax	$	4,295		$	3,861

Business Segment Information (Tables)

3 Months Ended

Mar. 29, 2014

Segment Reporting [Abstract]

Schedule of Sales and Other Financial Information by Business Segment

The following table presents sales and other financial information by business segment.



	Three Months Ended
	March 29, 2014		March 30, 2013
Research Models and Services
Revenue	$	185,615	$	182,489
Gross margin	80,979		80,435
Operating income	53,540		55,303
Depreciation and amortization	10,690		9,873
Capital expenditures	6,868		4,010
Preclinical Services
Revenue	$	113,753	$	108,749
Gross margin	27,834		23,776
Operating income	12,033		8,060
Depreciation and amortization	9,361		10,137
Capital expenditures	4,322		2,418

Reconciliation of Segment Operating Income to Consolidated Operating Income

A reconciliation of segment operating income to consolidated operating income is as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Total segment operating income	$	65,573		$	63,363
Unallocated corporate overhead	(25,867		)	(20,600		)
Consolidated operating income	$	39,706		$	42,763

Schedule of Net Sales for Each Significant Service Area

for each significant product or service area are as follows:



	Three Months Ended
	March 29, 2014		March 30, 2013
Research models	$	99,355	$	103,123
Research model services	53,795		52,154
EMD	32,465		27,212
Total research models and services	185,615		182,489
Total preclinical services	113,753		108,749
Total revenue	$	299,368	$	291,238

Summary of Unallocated Corporate Overhead

A summary of unallocated corporate overhead consists of the following:



	Three Months Ended
	March 29, 2014		March 30, 2013
Stock-based compensation expense	$	3,702	$	3,197
U.S. retirement plans	644		1,300
Audit, tax and related expense	1,906		1,235
Salary and bonus	6,139		4,755
Global IT	2,869		2,586
Employee health, long-term disability and fringe benefit expense	2,319		2,228
Consulting and professional services	1,182		688
Depreciation expense	1,600		1,570
Other general unallocated corporate expenses	5,506		3,041
Total unallocated corporate overhead costs	$	25,867	$	20,600

Discontinued Operations (Tables)

3 Months Ended

Mar. 29, 2014

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Operating Results from Discontinued Operations

Operating results from discontinued operations are as follows:



	Three Months Ended
	March 29, 2014			March 30, 2013
Income (loss) from operations of discontinued businesses, before income taxes	(25		)	(220		)
Provision (benefit) for income taxes	245			(65		)
Income (loss) from operations of discontinued businesses, net of taxes	$	(270	)	$	(155	)

Schedule of Assets and Liabilities of Discontinued Operations

Assets and liabilities of discontinued operations at March 29, 2014 and December 28, 2013 consisted of the following:



	March 29, 2014		December 28, 2013
Current assets	$	677	$	750
Long-term assets	2,970		3,151
Total assets	$	3,647	$	3,901
Current liabilities	$	1,747	$	1,931
Long-term liabilities	7,615		8,080
Total liabilities	$	9,362	$	10,011

Restructuring and Asset Impairments (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Jun. 28, 2014	Mar. 29, 2014	Mar. 30, 2013	Dec. 27, 2014
Restructuring Cost and Reserve [Line Items]
Accelerated depreciation estimate				$ 840
Severance and Retention Costs
Balance, beginning of period	$ 3,547	$ 2,782	$ 3,636	$ 3,547
Expense		1,900	297
Payments for Restructuring		(1,135)	(498)
Balance, end of period		3,547	3,435
Severance and retention costs, current		2,217
Severance and retention costs, noncurrent		1,330
Severance and retention costs		1,900	297
Research Models and Services [Member]
Severance and Retention Costs
Severance and retention costs		1,716	86
Preclinical Services [Member]
Severance and Retention Costs
Severance and retention costs		63	211
Corporate [Member]
Severance and Retention Costs
Severance and retention costs		121	0
General and Administrative Expense [Member]
Severance and Retention Costs
Severance and retention costs		218	70
Cost of Sales [Member]
Severance and Retention Costs
Severance and retention costs		1,682	$ 227
Portage, MI [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges		690
Accelerated depreciation estimate		$ 290
RMS Europe [Member]
Restructuring Cost and Reserve [Line Items]
Gain (Loss) on Disposition of Property Plant Equipment	$ 800

Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Dec. 28, 2013
Composition of trade receivables
Client receivables	$ 203,107	$ 190,423
Unbilled revenue	41,442	35,184
Total	244,549	225,607
Less allowance for doubtful accounts	(4,551)	(4,977)
Net trade receivables	239,998	220,630
Composition of inventories
Raw materials and supplies	15,012	15,028
Work in process	11,977	11,715
Finished products	64,685	62,653
Inventories	91,674	89,396
Composition of other current assets
Prepaid assets	24,316	20,058
Deferred tax asset	22,333	29,139
Marketable securities	11,446	11,158
Prepaid income tax	30,348	25,247
Restricted cash	16	245
Other current assets	88,459	85,847
Composition of other assets
Deferred financing costs	6,692	7,126
Cash surrender value of life insurance policies	26,780	26,507
Equity Method Investments	18,973	17,911
Other assets	11,598	10,420
Other assets	64,043	61,964
Composition of other current liabilities
Accrued income taxes	6,662	18,773
Current deferred tax liability	1,620	1,960
Accrued intereset and other	1,573	1,813
Other current liabilities	9,855	22,546
Composition of other long-term liabilities
Deferred tax liability	14,840	14,988
Long-term pension liability	15,864	16,219
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan	29,971	28,708
Other long-term liabilities	9,765	10,717
Other long-term liabilities	$ 70,440	$ 70,632

Supplemental Balance Sheet Information (Long-lived Assets) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Dec. 28, 2013
Net property, plant and equipment
Gross property, plant and equipment	$ 1,325,114		$ 1,321,709
Less accumulated depreciation	(659,505)		(645,527)
Net property, plant and equipment	665,609		676,182
Depreciation expense	15,710	$ 15,761
Land [Member]
Net property, plant and equipment
Gross property, plant and equipment	40,070		40,157
Buildings [Member]
Net property, plant and equipment
Gross property, plant and equipment	695,278		694,074
Machinery and Equipment [Member]
Net property, plant and equipment
Gross property, plant and equipment	374,180		367,244
Leashold Improvements [Member]
Net property, plant and equipment
Gross property, plant and equipment	38,404		37,959
Furniture and Fixtures [Member]
Net property, plant and equipment
Gross property, plant and equipment	24,448		24,013
Vehicles [Member]
Net property, plant and equipment
Gross property, plant and equipment	3,882		3,859
Computer Hardware and Software [Member]
Net property, plant and equipment
Gross property, plant and equipment	112,661		112,328
Construction in Progress [Member]
Net property, plant and equipment
Gross property, plant and equipment	$ 36,191		$ 42,075

Marketable Securities and Investments in Limited Partnerships (Marketable Securities) (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Dec. 28, 2013
Schedule of Available-for-sale Securities [Line Items]
Marketable Securities	$ 11,446	$ 11,158

Marketable Securities and Investments in Limited Partnerships (Investments in Limited Partnerships) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Dec. 28, 2013
Schedule of Equity Method Investments [Line Items]
Limited partnership, committed contribution	$ 35,000
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	13,829
Proceeds from Equity Method Investment, Dividends or Distributions	6,498
Income (loss) from investments in limited partnerships	6,104	$ (90)
Equity method affiliates, carrying value	$ 18,973		$ 17,911
Ownership percentage low range [Member]
Schedule of Equity Method Investments [Line Items]
Limited partnership, ownership (as a percentage)	3.80%
Ownership percentage high range [Member]
Schedule of Equity Method Investments [Line Items]
Limited partnership, ownership (as a percentage)	12.10%

Fair Value (Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Dec. 28, 2013	Jan. 04, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			25.00%
Fair Value Inputs, Discount Rate	18.00%
Available-for-sale Securities, Fair Value Disclosure	$ 11,446	$ 11,158
Fair value of life policies	19,747	19,534
Total assets measured at fair value	31,193	30,692
Redeemable Noncontrolling Interest, Equity, Fair Value	21,579	20,581
Total liabilities measured at fair value	$ 21,579	20,581
Fair Value Inputs, Long-term Pre-tax Operating Margin, Percent	32.00%
Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Hedge gains recorded	$ 575
Outstanding forward contract, fair value	0
Quoted Prices in Active Markets for Identical Assets Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	0	0
Fair value of life policies	0	0
Total assets measured at fair value	0	0
Redeemable Noncontrolling Interest, Equity, Fair Value	0	0
Total liabilities measured at fair value	0	0
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	11,446	11,158
Fair value of life policies	19,747	19,534
Total assets measured at fair value	31,193	30,692
Redeemable Noncontrolling Interest, Equity, Fair Value	0	0
Total liabilities measured at fair value	0	0
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	0	0
Fair value of life policies	0	0
Total assets measured at fair value	0	0
Redeemable Noncontrolling Interest, Equity, Fair Value	21,579	20,581
Total liabilities measured at fair value	$ 21,579	$ 20,581

Fair Value Level 3 Reconciliation Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Dec. 28, 2013	Dec. 29, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 21,579		$ 9,038	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net	0	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	1	38
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)	(476)	37
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	$ 1,473
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases		$ 8,963

Goodwill and Other Intangible Assets (Schedule of Goodwill and Other Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Gross Carrying Amount	$ 1,235,321	$ 1,235,701
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	328,932	333,008
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(252,919)	(251,909)
Backlog [Member]
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	2,916	2,916
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(2,533)	(2,507)
Client Relationships [Member]
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	307,383	311,507
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(238,138)	(238,002)
Trademarks and Trade Names [Member]
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	5,398	5,399
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(5,012)	(4,997)
Standard Operating Procedures [Member]
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	2,754	2,754
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(1,645)	(1,498)
Other Identifiable Intangible Assets [Member]
Other intangible assets
Other intangible assets subject to amortization, Gross Carrying Amount	10,481	10,432
Other intangible assets subject to amortization, Accumulated Amortization & Impairment Loss	(5,591)	(4,905)
Research Models [Member]
Other intangible assets
Other intangible assets not subject to amortization, Gross Carrying Amount	$ 3,438	$ 3,438

Goodwill and Other Intangible Assets (Gross Carrying Amount and Accumulated Amortization of Goodwill) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Dec. 28, 2013
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	$ 1,235,701
Gross carrying amount, acquired during the period	0
Gross carrying amount, foreign exchange/impairment	(380)
Accumulated impairment loss, balance at the beginning of the period	(1,005,000)
Goodwill	230,321	$ 230,701
Research Models and Services [Member]
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	83,551
Gross carrying amount, acquired during the period	0
Gross carrying amount, foreign exchange/impairment	(361)
Preclinical Services [Member]
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	1,152,150
Gross carrying amount, acquired during the period	0
Gross carrying amount, foreign exchange/impairment	(19)
Accumulated impairment loss, balance at the beginning of the period	$ (1,005,000)

Long-Term Debt and Capital Lease Obligations (Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Dec. 28, 2013
Debt Instrument
Principal	$ 640,094
Total debt	640,094	$ 663,049
Less: current portion of long-term debt	(26,491)	(21,241)
Long-term debt	613,603	641,808
Term loan facilities
Debt Instrument
Total debt	404,250	409,500
Revolving credit facility
Debt Instrument
Total debt	235,603	253,308
Other long-term debt
Debt Instrument
Total debt	$ 241	$ 241

Long-Term Debt and Capital Lease Obligations (Additional Disclosures) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Dec. 28, 2013
Debt Instrument [Line Items]
Maximum borrowing capacity, Term Loan and Line of Credit	$ 970,000
US Term Loan	420,000
Maximum borrowing capacity, Line of Credit	550,000
Credit Facility Borrowing Capacity Available Increase	$ 350,000
Debt Instrument, Basis Spread on Variable Rate	1.25%
Outstanding under letters of credit	$ 5,109
Long-term Debt, Excluding Current Maturities	613,603	$ 641,808
Capital lease obligations	717	$ 740
Principal maturities of existing debt excluding unamortized debt discount
March 2015	26,491
March 2016	42,000
March 2017	52,500
March 2018	73,500
March 2019	445,603
Total	$ 640,094

Equity (Earnings Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Numerator:
Income from continuing operations for purposes of calculating earnings per share	$ 32,502	$ 25,733
Income (loss) from discontinued operations	$ (270)	$ (155)
Denominator:
Weighted average shares outstanding-Basic (in shares)	47,090,830	47,658,995
Effect of dilutive securities:
Stock options and contingently issued restricted stock (in shares)	1,060,554	777,054
Weighted Average Number of Shares Outstanding, Diluted	48,151,384	48,436,049
Basic earnings per share from continuing operations attributable to common shareowners (in dollars per share)	$ 0.69	$ 0.54
Basic earnings (loss) per share from discontinued operations attributable to common shareowners (in dollars per share)	(0.01)	0.00
Diluted earnings per share from continuing operations attributable to common shareowners (in dollars per share)	0.67	0.53
Diluted earnings (loss) per share from discontinued operations attributable to common shareowners (in dollars per share)	$ (0.01)	$ 0.00
2.25% Senior convertible debentures
Effect of dilutive securities:
Interest rate on debt (as a percent)	2.25%
Stock options [Member]
Antidilutive securities excluded from computation of earnings per share amount
Antidilutive securities excluded from computation of earnings per share amount (in shares)	609,923	2,684,236
Restricted Stock [Member]
Antidilutive securities excluded from computation of earnings per share amount
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1,188,699	1,149,622

Equity (Treasury Stock) (Details) - USD ($) $ in Thousands	3 Months Ended
Equity (Treasury Stock) (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Mar. 30, 2013
Treasury Shares
Number of shares of common stock repurchased (in shares)	296,047	268,798
Total cost of repurchase of treasury shares	$ 16,474	$ 10,929
Open market repurchases
Treasury Shares
Number of shares of common stock repurchased (in shares)	183,300	157,283
Total cost of repurchase of treasury shares	$ 9,820	$ 6,458
2007 Incentive Plan
Treasury Shares
Number of shares of common stock repurchased (in shares)	112,747	111,515
Total cost of repurchase of treasury shares	$ 6,654	$ 4,471

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Mar. 30, 2013
Income (loss) from continuing operations before income taxes
Income from continuing operations, before income taxes	$ 42,986	$ 35,648
Effective tax rate (as a percentage)	24.10%	27.30%
Provision (benefit) for income taxes	$ 10,358	$ 9,722
Other Comprehensive Income (Loss), Tax [Abstract]
Income tax expense (beneffit) related to foreign currency translation adjustments	(105)	662
Income tax expense related to the change in unrecognized pension gains, losses and prior service costs	124	242
Income tax expense (benefit) related to items of other comprehensive income	19	$ 904
Income Tax Uncertainties [Abstract]
Unrecognized Tax Benefits, Period Increase (Decrease)	(2,563)
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities	24
Interest related to unrecognized income tax benefits	667
Unrecognized tax benefits	15,912
Decrease in unrecognized tax benefits, that if recognized would impact the effective tax rate	2,719
Unrecognized tax benefits that would impact effective tax rate favorably, if recognized	14,293
UNITED STATES
Income Tax Uncertainties [Abstract]
Unrecognized Tax Benefits, Period Increase (Decrease)	1,837
CANADA
Income Tax Disclosures [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions	$ 238

Employee Benefits (Details) - USD ($) $ in Thousands	3 Months Ended
Employee Benefits (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Mar. 30, 2013
OPEB [Member]
Employee benefits
Amortization of net loss (gain)	$ (3)	$ (31)
Pension Benefits [Member]
Employee benefits
Service cost	842	847
Interest cost	3,211	2,810
Expected return on plan assets	(4,278)	(3,656)
Amortization of prior service cost (credit)	(159)	(150)
Amortization of net loss (gain)	223	690
Net periodic benefit cost	(161)	541
Expected contributions during the current fiscal year	6,477
Supplemental Employee Retirement Plan, Defined Benefit [Member]
Employee benefits
Service cost	189	161
Interest cost	252	177
Expected return on plan assets	0	0
Amortization of prior service cost (credit)	165	165
Amortization of net loss (gain)	63	63
Net periodic benefit cost	$ 669	$ 566

Stock Plans and Stock-Based Compensation Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Stock-based compensation expense
Stock-based compensation expense	$ 6,659	$ 5,904
Provision for income taxes	(2,364)	(2,043)
Net income attributable to common shareowners	4,295	3,861
Cost of Sales [Member]
Stock-based compensation expense
Stock-based compensation expense	1,353	1,369
General and Administrative Expense [Member]
Stock-based compensation expense
Stock-based compensation expense	5,306	$ 4,535
Performance Based Stock Award Program [Member]
Stock-based compensation expense
Stock-based compensation expense	$ 1,034

Stock Plans and Stock-Based Compensation Performance Based Stock Award Program (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 29, 2014	Mar. 31, 2012
2013 PSU [Member]
Restricted Stock and Performance Units, Additional Disclosure
Max PSU Shares	328
Granted (in dollars per share)		$ 40
Granted (in shares)		163,847
2014 PSU [Member]
Restricted Stock and Performance Units, Additional Disclosure
Max PSU Shares	429,646
Granted (in dollars per share)	$ 67,820
Granted (in shares)	214,823

Commitments and Contingencies Details (Details) $ in Thousands	Mar. 29, 2014 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Estimate of Possible Loss	$ 1,500

Business Segment Information (Details) $ in Thousands	3 Months Ended
Business Segment Information (Details) $ in Thousands	Mar. 29, 2014 USD ($) segments	Mar. 30, 2013 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segments	2
Business segment information
Revenue	$ 299,368	$ 291,238
Operating income	39,706	42,763
Depreciation and amortization	20,050	20,010
Capital expenditures	11,190	6,429
Unallocated corporate overhead
Stock-based compensation expense	6,659	5,904
Depreciation expense	15,710	15,761
Research Models [Member]
Business segment information
Revenue	99,355	103,123
Research Model Services [Member]
Business segment information
Revenue	53,795	52,154
Other Products [Member]
Business segment information
Revenue	32,465	27,212
Total Segments [Member]
Business segment information
Operating income	65,573	63,363
Research Models and Services [Member]
Business segment information
Revenue	185,615	182,489
Gross margin	80,979	80,435
Operating income	53,540	55,303
Depreciation and amortization	10,690	9,873
Capital expenditures	6,868	4,010
Preclinical Services [Member]
Business segment information
Revenue	113,753	108,749
Gross margin	27,834	23,776
Operating income	12,033	8,060
Depreciation and amortization	9,361	10,137
Capital expenditures	4,322	2,418
Unallocated Corporate Overhead [Member]
Business segment information
Operating income	(25,867)	(20,600)
Unallocated corporate overhead
Stock-based compensation expense	3,702	3,197
U.S. retirement plans	644	1,300
Audit, tax and related expenses	1,906	1,235
Salary and bonus	6,139	4,755
Global IT	2,869	2,586
Employee health, long-term disability and fringe benefit expense	2,319	2,228
Consulting and professional services	1,182	688
Depreciation expense	1,600	1,570
Other general unallocated corporate expenses	5,506	3,041
Total unallocated corporate overhead costs	$ 25,867	$ 20,600

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
Discontinued Operations (Details) - USD ($) $ in Thousands	Mar. 29, 2014	Mar. 30, 2013	Dec. 28, 2013
Operating results from discontinued operations
Income (loss) from operations of discontinued businesses, net of taxes	$ (270)	$ (155)
Assets and liabilities of discontinued operations
Current assets	677		$ 750
Long-term assets	2,970		3,151
Current liabilities	1,747		1,931
Long-term liabilities	7,615		8,080
Phase I Clinical [Member]
Operating results from discontinued operations
Facility lease payments	11,070
Income (loss) from operatoins of discontinued businesses, before income taxes	(25)	(220)
Provision (benefit) for income taxes	245	(65)
Income (loss) from operations of discontinued businesses, net of taxes	(270)	$ (155)
Assets and liabilities of discontinued operations
Current assets	677		750
Long-term assets	2,970		3,151
Total assets	3,647		3,901
Current liabilities	1,747		1,931
Long-term liabilities	7,615		8,080
Total liabilities	9,362		$ 10,011
Guarantor Obligations, Current Carrying Value	$ 9,345

Business Acquisitions Business Acquisition Details (Details) - Early Discovery UK [Member] $ in Thousands	3 Months Ended
	Mar. 29, 2014 USD ($)
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Purchase Price	$ 190,727
Business Acquisition, Effective Date of Acquisition	Apr. 01, 2014
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 6,887

Label	Element	Value
Goodwill, Impaired, Accumulated Impairment Loss	us-gaap_GoodwillImpairedAccumulatedImpairmentLoss	$ 1,005,000,000
Research Models and Services [Member]
Goodwill, Gross	us-gaap_GoodwillGross	83,190,000
Preclinical Services [Member]
Goodwill, Impaired, Accumulated Impairment Loss	us-gaap_GoodwillImpairedAccumulatedImpairmentLoss	1,005,000,000
Goodwill, Gross	us-gaap_GoodwillGross	$ 1,152,131,000